TY - JOUR T1 - Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia JF - Anticancer Research JO - Anticancer Res SP - 713 LP - 717 VL - 37 IS - 2 AU - SUSAN K. WOELICH AU - JAMES T. BRAUN AU - MARTIN W. SCHOEN AU - RESHMA RAMLAL AU - CARL E. FRETER AU - PAUL J. PETRUSKA AU - JACK M. LIONBERGER Y1 - 2017/02/01 UR - http://ar.iiarjournals.org/content/37/2/713.abstract N2 - We report our single-center experience with cytarabine and idarubicin for induction therapy for acute myeloid leukemia (AML) with an additional 5 days of cladribine (IAC therapy). From July 2012 to September 2014, 38 patients completed a full course of IAC induction. Median patient age was 61 years, 61% of patients were ≥60 years old, and 71% were male. The complete remission (CR) rate was 63% following a single induction course, three patients (8%) required a second induction course to achieve CR, for an overall response rate of 71%. The median duration of severe neutropenia was 30.5 days. Thirty-two percent of patients developed mucositis, 76% experienced diarrhea, and 61% developed a rash. Incidence of CR following IAC induction therapy for AML was comparable to historical data, but with frequent diarrhea, rash, and fungal infections. This study found IAC efficacy and toxicity was similar irrespective of age. ER -